Eversense 365, an implantable continuous glucose monitor (CGM), is indicated for people with type 1 and type 2 diabetes aged 18 years and older.
Senseonics announced last month that it received FDA clearance for Eversense 365. With the clearance, it became the world’s first 365-day CGM system, according to the company.